Global Neuromyelitis Optica Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
According to our (Global Info Research) latest study, the global Neuromyelitis Optica Drug market size was valued at USD 48 million in 2022 and is forecast to a readjusted size of USD 59 million by 2029 with a CAGR of 2.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neuromyelitis Optica Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz and Intas, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neuromyelitis Optica Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    Glucocorticoids
    Immunotherapies
    Others
Market segment by Application
    Acute Attack
    Remission Prophylactic Treatment
Market segment by players, this report covers
    Pfizer
    Fresenius
    Teva
    Sandoz
    Intas
    Gyjtrs
    NANG KUANG
    Tianjin Kingyork
    Baxter
    CSL
    Grifols
    Octapharma
    CBOP
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neuromyelitis Optica Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Drug, with revenue, gross margin and global market share of Neuromyelitis Optica Drug from 2018 to 2023.
Chapter 3, the Neuromyelitis Optica Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neuromyelitis Optica Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Drug.
Chapter 13, to describe Neuromyelitis Optica Drug research findings and conclusion.